You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三葉草及信達生物跌逾5% 百心安挫24% 百濟神州及騰盛博藥回升近3%至6%
內地出台第七批國家集採中選藥品涉60種平均降價48%後,醫藥板塊連續第二天榮辱互見。騰盛博藥-B(02137.HK)回落守穩20天線(8.17元),今天高見8.88元,現報8.75元,回升5.7%。百濟神州(06160.HK)盤中曾高見119.2元,現報118.2元,回升近3%。 藍籌中生製藥(01177.HK)回升1.6%曾高見4.58元。同為藍籌翰森製藥(03692.HK)和藥明生物(02269.HK)反覆續升1.1%及0.8%,報15元及51.05元。康希諾(06185.HK)及開拓藥業-B(09939.HK)反覆回升0.9%-1.7%,各報90.6元及12.86元。 相反,三葉草生物-B(02197.HK)兩連跌後,今天高低見4.87元/4.31元,現報4.46元,反覆續跌4.9%。信達生物(01801.HK)今日股價高低見30.8元/28元,現報28.1元,反覆續跌5.2%。康方生物(09926.HK)反覆回吐4%報32.4元,股價失守10天線(33.1元)。再鼎醫藥-B(09688.HK)及藥明康德(02359.HK)回吐1.7%-2.7%,各報28.3元及74.85元。 此外,內地創新介入式心血管裝置公司的百心安-B(02185.HK)兩連跌後,今日曾回升至14.02元無以為繼,掉頭再創上市新低,盤中曾低見8.65元,現報9.87元,續挫24%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account